Clinical Trial Update: Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating imatinib mesylate in patients with metastatic breast cancer has completed and was updated in ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Imatinib Mesylate (Gleevec) (Imatinib mesylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Male Breast Cancer, Recurrent Breast Cancer | Phase 2 | Status: COMPLETED